SEARCH

MEDIA PACK

NEWS

Current Edition

immunotherapy

Roche ushers early lung cancer into immunotherapy era with Tecentriq FDA approval. Will doctors follow?

Roche’s Tecentriq has ushered in a new era, offering the first immunotherapy option for non-small cell lung cancer (NSCLC) patients right after tumour surgery. But …

20 October 2021 Regional News immunotherapy lung cancer

Continue Reading →

breast

Tecentriq extends streak with win in breast cancer trial

Roche’s checkpoint inhibitor Tecentriq helped extend progression-free survival in a Phase 3 study of patients with a hard-to-treat form of metastatic breast cancer, a milestone …

4 July 2018 Europe news breast cancer

Continue Reading →

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

SEARCH

MENU

Current Edition

Roche ushers early lung cancer into immunotherapy era with Tecentriq FDA approval. Will doctors follow?

Tecentriq extends streak with win in breast cancer trial

Journal for Clinical Studies